biostudies-literatureThela LAD Strategic Fund and the Alzheimer's AssociationSwedish Research CouncilAlzheimer Drug Discovery FoundationUniversity of Cape TownEuropean Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreementEuropean Union Joint Programme – Neurodegenerative Disease ResearchAD Strategic Fund and the Alzheimer's AssociationEuropean Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreementEuropean Research CouncilUK Dementia Research Institute at UCLOlav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, SwedenSwedish state under an agreement between the Swedish government and the county councilsEuropean Union Joint Programme - Neurodegenerative Disease ResearchSwedish State Support for Clinical Research156-166https://www.ebi.ac.uk/biostudies/studies/S-EPMC10185609biostudies-literatureUnknown29(2)HIV-associated neurocognitive disorders (HAND) persist in the era of antiretroviral therapy (ART). Thus, ART does not completely halt or reverse the pathological processes behind HAND. Adjuvant mitigating treatments are, therefore, prudent. Lithium treatment is known to promote neuronal brain-derived neurotrophic factors (BDNF). Lithium is also an inhibitor of glycogen synthase kinase-3 beta (GSK-3-β). We analyzed biomarkers obtained from participants in a randomized placebo-controlled trial of lithium in ART-treated individuals with moderate or severe HAND. We assayed markers at baseline and 24 weeks across several pathways hypothesized to be affected by HIV, inflammation, or degeneration. Investigated biomarkers included dopamine, BDNF, neurofilament light chain, and CD8 + lymphocyte actJournal of neurovirologyBlood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial.PMC10185609#2018-02532#681712860197#ADSF-21-831377-CUKDRI-1003#ADSF-21-831376-C#ADSF-21-831381-C#101053962JPND2021-00694ALFGBG-965885#ALFGBG-71320101053962681712#201809-2016862#FO2019-0228Gisslen MJoska JThela LKoutsilieri EDecloedt EHye AZetterberg HLesosky MScheller CGleich MfalseBlood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial.HIV-associated neurocognitive disorders (HAND) persist in the era of antiretroviral therapy (ART). Thus, ART does not completely halt or reverse the pathological processes behind HAND. Adjuvant mitigating treatments are, therefore, prudent. Lithium treatment is known to promote neuronal brain-derived neurotrophic factors (BDNF). Lithium is also an inhibitor of glycogen synthase kinase-3 beta (GSK-3-β). We analyzed biomarkers obtained from participants in a randomized placebo-controlled trial of lithium in ART-treated individuals with moderate or severe HAND. We assayed markers at baseline and 24 weeks across several pathways hypothesized to be affected by HIV, inflammation, or degeneration. Investigated biomarkers included dopamine, BDNF, neurofilament light chain, and CD8 + lymphocyte act2023-01-01T00:00:00Z2023 Apr2025-04-22T14:44:23.535Z2025-04-06T01:05:02.545ZS-EPMC101856093679060110.1007/s13365-023-01116-4